Eli Lilly and Company $LLY Shares Sold by B. Metzler seel. Sohn & Co. AG

Key Points

• B. Metzler seel. Sohn & Co. AG reduced its Eli Lilly stake by 13.8%, selling 19,277 shares and ending the quarter with 120,516 shares worth about $129.7 million (LLY is ~1.1% of the fund and its 20th largest holding).
• Wall Street remains largely bullish with multiple price‑target increases (Bank of America, JPMorgan, Cantor Fitzgerald among others) and an average target near $1,225, giving the stock a consensus "Moderate Buy" rating.
• Near‑term risks persist as Lilly's new obesity pill Foundayo has a softer early uptake (~3,707 second‑week U.S. prescriptions) and weekly GLP‑1 script data are mixed, making the upcoming Q1 earnings (a near‑term catalyst) especially important.

B. Metzler seel. Sohn & Co. AG lowered its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 13.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 120,516 shares of the company's stock after selling 19,277 shares during the quarter. Eli Lilly and Company makes up about 1.1% of B. Metzler seel. Sohn & Co. AG's holdings, making the stock its 20th largest holding. B. Metzler seel. Sohn & Co. AG's holdings in Eli Lilly and Company were worth $129,700,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Exencial Wealth Advisors LLC increased its stake in Eli Lilly and Company by 189.6% during the third quarter. Exencial Wealth Advisors LLC now owns 17,408 shares of the company's stock worth $13,283,000 after acquiring an additional 11,396 shares during the last quarter. Rede Wealth LLC acquired a new stake in Eli Lilly and Company during the third quarter worth $487,000. Cidel Asset Management Inc. increased its stake in Eli Lilly and Company by 26.5% during the third quarter. Cidel Asset Management Inc. now owns 26,726 shares of the company's stock worth $20,392,000 after acquiring an additional 5,591 shares during the last quarter. Spire Wealth Management increased its stake in Eli Lilly and Company by 2.2% during the fourth quarter. Spire Wealth Management now owns 27,719 shares of the company's stock worth $29,789,000 after acquiring an additional 592 shares during the last quarter. Finally, Coldstream Capital Management Inc. increased its stake in Eli Lilly and Company by 25.6% during the third quarter. Coldstream Capital Management Inc. now owns 42,418 shares of the company's stock worth $32,365,000 after acquiring an additional 8,659 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the company. Rothschild & Co Redburn raised their target price on Eli Lilly and Company from $875.00 to $880.00 and gave the stock a "neutral" rating in a research note on Friday, April 10th. Bank of America raised their target price on Eli Lilly and Company from $1,293.00 to $1,294.00 and gave the stock a "buy" rating in a research note on Thursday, April 2nd. JPMorgan Chase & Co. raised their target price on Eli Lilly and Company from $1,150.00 to $1,300.00 and gave the stock an "overweight" rating in a research note on Thursday, February 5th. Weiss Ratings restated a "buy (b)" rating on shares of Eli Lilly and Company in a research report on Friday, March 27th. Finally, Cantor Fitzgerald raised their price target on Eli Lilly and Company from $985.00 to $1,205.00 and gave the stock an "overweight" rating in a research report on Thursday, February 5th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Eli Lilly and Company has an average rating of "Moderate Buy" and an average target price of $1,225.33.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Analyst upgrades and higher targets provide support for the shares — firms have recently raised price targets and reiterated bullish views, which underpins medium‑term confidence in execution. Price Target Raised to $1,183.00
• Positive Sentiment: Expanded distribution partnerships broaden commercial reach: Lilly expanded its tie‑up with Hims & Hers to allow prescriptions filled via LillyDirect, increasing patient access to GLP‑1s and Zepbound. This helps commercialization and channel diversification. Eli Lilly (LLY) Expands Partnership with Hims & Hers
• Positive Sentiment: M&A and pipeline progress: recent reports list Lilly acquiring Kelonia (~$7B) and completing a Phase 1 renal study (LY3537982), which reduce early‑stage risk and add potential growth assets. These are constructive for long‑term revenue diversity. Deal Dispatch (mentions Lilly/Kelonia) LY3537982 Renal Study Reaches Completion
• Neutral Sentiment: Upcoming earnings (Q1 report due April 30) is a near‑term catalyst that can amplify moves in either direction — investors are sensitive to any GLP‑1 demand readouts ahead of that release. Weekly GLP-1 prescription data analysis
• Negative Sentiment: Foundayo rollout is tracking below expectations — second‑week U.S. prescriptions were ~3,707, a much smaller early ramp than Novo Nordisk’s oral Wegovy benchmark, raising investor concerns about near‑term obesity market share and pricing/mix. That weaker early uptake is the primary reason shares are under pressure today. Lilly's obesity pill hits nearly 4000 prescriptions
• Negative Sentiment: Weekly GLP‑1 prescription trackers show mixed demand signals (diabetes scripts steady but obesity scripts softer), and heavy insider selling / shifting institutional flows noted in some data sources add to short‑term sentiment risk. Prescription data and insider activity

Eli Lilly and Company Trading Up 0.1%

LLY opened at $884.88 on Monday. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,133.95. The business has a fifty day simple moving average of $958.83 and a 200-day simple moving average of $985.86. The firm has a market cap of $836.05 billion, a P/E ratio of 38.56, a P/E/G ratio of 1.05 and a beta of 0.51. The company has a quick ratio of 1.19, a current ratio of 1.58 and a debt-to-equity ratio of 1.54.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings results on Wednesday, February 4th. The company reported $7.54 EPS for the quarter, topping the consensus estimate of $7.48 by $0.06. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The business had revenue of $19.29 billion during the quarter, compared to analyst estimates of $17.85 billion. During the same period last year, the business posted $5.32 earnings per share. The company's quarterly revenue was up 42.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. On average, equities analysts expect that Eli Lilly and Company will post 33.9 earnings per share for the current year.

Eli Lilly and Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.